Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer (NeoEribulin)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by SOLTI Breast Cancer Research Group
Sponsor:
Collaborator:
Eisai Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier:
NCT01669252
First received: August 9, 2012
Last updated: May 12, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)